Area of research
Genetics · Pathology and Forensic Medicine
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Immunodeficiency and Autoimmune Disorders, and Acute Lymphoblastic Leukemia research.
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia
The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia.
Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.
Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia.
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.
International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendations
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
Surrogate endpoints in mature B-cell neoplasms - meaningful or misleading?
ELEVATE-ing clinical trial reporting in CLL.
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Clonal Hematopoiesis in Patients with Chronic Lymphocytic Leukemia Treated with Fixed-Duration Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Insights from the Randomized CLL14 Trial
Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More?
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
RETRACTED ARTICLE: Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Body composition and lung cancer-associated cachexia in TRACERx
Body composition and lung cancer-associated cachexia in TRACERx.
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.
Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
TP53 mutations in CLL: does frequency matter?
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial.